Phase 1b results for Nintedanib DPI in IPF patients showed strong safety and tolerability, with no serious adverse events or discontinuations. The DPI formulation achieved efficient lung delivery and high peak concentrations, supporting its potential as a backbone therapy for IPF as Phase 2 enrollment progresses.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.